3-nitropropionic acid has been researched along with oxidopamine in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (36.36) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ebendal, T; Pei, G | 1 |
| Carter, RJ; Morton, AJ; Reynolds, DS | 1 |
| Geddes, JW; Jakel, RJ; Maragos, WF; Pang, Z | 1 |
| Chesnut, MD; Dwoskin, LP; Geddes, JW; Jakel, RJ; Maragos, WF | 1 |
| Baker, D; Cabranes, A; de Lago, E; Fernández-Ruiz, J; López-Rodríguez, M; Ortega-Gutiérrez, S; Pryce, G; Ramos, JA | 1 |
| Diaz-Muñoz, M; Garcia, E; Giordano, M; Herrera-Mundo, MN; Limon, D; Maldonado, PD; Pedraza-Chaverri, J; Perez-De La Cruz, V; Santamaria, A | 1 |
| Alvarez-Fischer, D; Bouillot, C; Castagner, F; Faigle, W; Fuchs, J; Hartmann, A; Joshi, RL; Lombès, A; Massiani-Beaudoin, O; Moya, KL; Oertel, WH; Prochiantz, A; Stettler, O | 1 |
| Akopian, G; Crawford, C; Jakowec, MW; Petzinger, G; Walsh, JP | 1 |
| Cai, AL; Sheline, CT; Shi, C; Zhang, W; Zhu, J | 1 |
| Benítez-Valenzuela, J; Colín-González, AL; de Jesús Negrete-Ruíz, M; Martínez-Sánchez, JE; Maya-López, M; Parra-Cid, C; Rangel-López, E; Ruiz-Contreras, HA; Sánchez-Chapul, L; Santamaría, A; Villeda-Hernández, J | 1 |
| Bachani, M; Johnson, TP; Lee, MH; Malik, N; Nath, A; Ruffin, A; Steiner, JP; Toodle, V; Vivekanandhan, S; Wang, T | 1 |
11 other study(ies) available for 3-nitropropionic acid and oxidopamine
| Article | Year |
|---|---|
Specific lesions in the extrapyramidal system of the rat brain induced by 3-nitropropionic acid (3-NPA).
Topics: Animals; Base Sequence; Behavior, Animal; Brain Diseases; Corpus Striatum; Dopamine; Female; Male; Molecular Sequence Data; Nerve Growth Factors; Nitro Compounds; Oxidopamine; Propionates; Rats; Rats, Sprague-Dawley; Receptors, Nerve Growth Factor; RNA, Messenger; Substantia Nigra; Tegmentum Mesencephali; Tyrosine 3-Monooxygenase | 1995 |
Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's disease.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzazepines; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Drug Interactions; Female; Huntington Disease; Methamphetamine; Microglia; Nerve Degeneration; Neurons; Nitro Compounds; Oxidopamine; Propionates; Rats; Rats, Sprague-Dawley; Substantia Nigra; Sympatholytics; Sympathomimetics | 1998 |
6-Hydroxydopamine injections into the nigrostriatal pathway attenuate striatal malonate and 3-nitropropionic acid lesions.
Topics: Animals; Antihypertensive Agents; Corpus Striatum; Denervation; Male; Malonates; Mitochondria; Nerve Degeneration; Neural Pathways; Neurotoxins; Nitro Compounds; Oxidative Stress; Oxidopamine; Propionates; Rats; Rats, Sprague-Dawley; Substantia Nigra; Succinate Dehydrogenase; Sympatholytics | 1998 |
Does dopamine contribute to striatal damage caused by impaired mitochondrial function?
Topics: Animals; Apomorphine; Biological Transport; Clorgyline; Corpus Striatum; Dopamine; Malonates; Medial Forebrain Bundle; Mitochondria; Monoamine Oxidase Inhibitors; Nitro Compounds; Oxidopamine; Propionates; Rats; Selegiline; Substantia Nigra | 1999 |
UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Arachidonic Acids; Brain Chemistry; Disease Models, Animal; Disease Progression; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; Encephalomyelitis, Autoimmune, Experimental; Endocannabinoids; Exploratory Behavior; Furans; gamma-Aminobutyric Acid; Glutamate Decarboxylase; Glutamic Acid; Huntington Disease; Male; Malonates; Movement Disorders; Multiple Sclerosis; Nitro Compounds; Oxidopamine; Polyunsaturated Alkamides; Propionates; Rats; Rats, Sprague-Dawley; Time Factors; Tyrosine 3-Monooxygenase | 2006 |
Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Basal Ganglia; Behavior, Animal; Biomarkers; Cysteine; Disease Models, Animal; Dopamine; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mitochondria; Motor Activity; MPTP Poisoning; Neuroprotective Agents; Neurotoxicity Syndromes; Nitro Compounds; Oxidative Stress; Oxidopamine; Propionates; Rats; Rats, Wistar; Synaptosomes; Time Factors | 2008 |
Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults.
Topics: alpha-Synuclein; Animals; Cell Count; Cells, Cultured; Chromatography, High Pressure Liquid; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Electron Transport Chain Complex Proteins; Embryo, Mammalian; Homeodomain Proteins; In Vitro Techniques; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Transgenic; NADH Dehydrogenase; Nerve Tissue Proteins; Neurons; Neurotoxins; Nitro Compounds; Oxidopamine; Propionates; RNA, Small Interfering; Rotenone; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2011 |
Brief mitochondrial inhibition causes lasting changes in motor behavior and corticostriatal synaptic physiology in the Fischer 344 rat.
Topics: Adrenergic Agents; Analysis of Variance; Animals; Benzazepines; Biophysics; Cerebral Cortex; Corpus Striatum; Dizocilpine Maleate; Dopamine Antagonists; Dose-Response Relationship, Drug; Electric Stimulation; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; Functional Laterality; In Vitro Techniques; Movement; Nitro Compounds; Oxidopamine; Propionates; Protein Binding; Rats; Rats, Inbred F344; Substantia Nigra; Sulpiride; Synapses; Time Factors; Tritium; Tyrosine 3-Monooxygenase | 2012 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; Cell Death; Cells, Cultured; Cerebral Cortex; Dihydroxyacetone Phosphate; Disease Models, Animal; Drug Interactions; Embryo, Mammalian; Fructose-Bisphosphatase; Humans; Huntington Disease; Male; Matrix Metalloproteinase 16; Membrane Proteins; Membrane Transport Proteins; Mental Disorders; Mice; Mice, Inbred C57BL; Mice, Neurologic Mutants; Mice, Transgenic; NAD; Neurons; Niacinamide; Nitro Compounds; Oxidopamine; Parkinson Disease; Propionates; Pyruvic Acid; Rats; Rats, Long-Evans; Tyrosine 3-Monooxygenase; Zinc | 2013 |
URB597 reduces biochemical, behavioral and morphological alterations in two neurotoxic models in rats.
Topics: Amidohydrolases; Animals; Apomorphine; Behavior, Animal; Benzamides; Body Weight; Carbamates; Injections; Lipid Peroxidation; Male; Motor Skills; Neostriatum; Neuroprotective Agents; Neurotoxicity Syndromes; Nitro Compounds; Oxidopamine; Propionates; Rats; Rats, Wistar | 2017 |
Fluconazole Is Neuroprotective via Interactions with the IGF-1 Receptor.
Topics: Animals; Antifungal Agents; D-Aspartic Acid; Fluconazole; Insulins; Neurodegenerative Diseases; Neuroprotection; Neuroprotective Agents; Oxidopamine; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1 | 2022 |